Nurix Therapeutics
Price & Volume
Stats
See more| Open | $20.90 |
| Previous Close | $20.87 |
| Day Range | $20.20-$22.16 |
| 52W Range | $4.22-$22.43 |
| Market Cap | $1.2B |
| Shares Short | 7M |
Financials
See more| Revenue (12 Mos) | $80.8M |
| Revenue Growth (YoY) | 30.7% |
| Gross Profit (12 Mos) | -$145.8M |
| Diluted EPS | -$2.66 |
News
See moreYahoo Finance • 7 months ago
Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting
Yahoo Finance • 8 months ago
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Nurix Therapeutics, Inc. (NASDAQ: NRIX) and Encourages Investors to Contact the Firm
Yahoo Finance • 8 months ago
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Yahoo Finance • 8 months ago
Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting
About
| CEO | Dr. Arthur T. Sands M.D., Ph.D. |
| Address | 1700 Owens Street, San Francisco, CA, United States, 94158 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Full-Time Employees | 284 |
